Multi-objective  ||| S:0 E:16 ||| JJ
optimisation  ||| S:16 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
stent  ||| S:32 E:38 ||| JJ
dilation  ||| S:38 E:47 ||| JJ
strategy  ||| S:47 E:56 ||| NN
in  ||| S:56 E:59 ||| IN
a  ||| S:59 E:61 ||| DT
patient-specific  ||| S:61 E:78 ||| JJ
coronary  ||| S:78 E:87 ||| JJ
artery  ||| S:87 E:94 ||| NN
via  ||| S:94 E:98 ||| IN
computational  ||| S:98 E:112 ||| NN
and  ||| S:112 E:116 ||| CC
surrogate  ||| S:116 E:126 ||| JJ
modelling  ||| S:126 E:136 ||| NN
Although  ||| S:136 E:145 ||| IN
contemporary  ||| S:145 E:158 ||| JJ
stents  ||| S:158 E:165 ||| NNS
have  ||| S:165 E:170 ||| VBP
been  ||| S:170 E:175 ||| VBN
shown  ||| S:175 E:181 ||| VBN
to  ||| S:181 E:184 ||| TO
improve  ||| S:184 E:192 ||| VB
short  ||| S:192 E:198 ||| JJ
and  ||| S:198 E:202 ||| CC
long  ||| S:202 E:207 ||| JJ
term  ||| S:207 E:212 ||| NN
clinical  ||| S:212 E:221 ||| JJ
outcomes ||| S:221 E:229 ||| NNS
,  ||| S:229 E:231 ||| ,
the  ||| S:231 E:235 ||| DT
optimum  ||| S:235 E:243 ||| JJ
dilation  ||| S:243 E:252 ||| JJ
protocol  ||| S:252 E:261 ||| NN
is  ||| S:261 E:264 ||| VBZ
still  ||| S:264 E:270 ||| RB
uncertain  ||| S:270 E:280 ||| JJ
in  ||| S:280 E:283 ||| IN
challenging  ||| S:283 E:295 ||| VBG
cases  ||| S:295 E:301 ||| NNS
characterised  ||| S:301 E:315 ||| VBN
by  ||| S:315 E:318 ||| IN
long ||| S:318 E:322 ||| JJ
,  ||| S:322 E:324 ||| ,
highly  ||| S:324 E:331 ||| RB
calcified  ||| S:331 E:341 ||| JJ
and  ||| S:341 E:345 ||| CC
tortuous  ||| S:345 E:354 ||| JJ
anatomy ||| S:354 E:361 ||| NN
.  ||| S:361 E:363 ||| .
Recent  ||| S:363 E:370 ||| JJ
clinical  ||| S:370 E:379 ||| JJ
studies  ||| S:379 E:387 ||| NNS
have  ||| S:387 E:392 ||| VBP
revealed  ||| S:392 E:401 ||| VBN
that  ||| S:401 E:406 ||| IN
in  ||| S:406 E:409 ||| IN
these  ||| S:409 E:415 ||| DT
cases ||| S:415 E:420 ||| NNS
,  ||| S:420 E:422 ||| ,
sub-optimal  ||| S:422 E:434 ||| JJ
delivery  ||| S:434 E:443 ||| NN
can  ||| S:443 E:447 ||| MD
result  ||| S:447 E:454 ||| VB
in  ||| S:454 E:457 ||| IN
stent  ||| S:457 E:463 ||| JJ
thrombosis  ||| S:463 E:474 ||| NNS
( ||| S:474 E:475 ||| -LRB-
ST ||| S:475 E:477 ||| NNP
)  ||| S:477 E:479 ||| -RRB-
and ||| S:479 E:482 ||| CC
/ ||| S:482 E:483 ||| NNP
or  ||| S:483 E:486 ||| CC
neointimal  ||| S:486 E:497 ||| JJ
thickening  ||| S:497 E:508 ||| NN
as  ||| S:508 E:511 ||| IN
a  ||| S:511 E:513 ||| DT
result  ||| S:513 E:520 ||| NN
of  ||| S:520 E:523 ||| IN
stent  ||| S:523 E:529 ||| JJ
malapposition  ||| S:529 E:543 ||| NNS
( ||| S:543 E:544 ||| -LRB-
SM ||| S:544 E:546 ||| NNP
)  ||| S:546 E:548 ||| -RRB-
and ||| S:548 E:551 ||| CC
/ ||| S:551 E:552 ||| NNP
or  ||| S:552 E:555 ||| CC
severe  ||| S:555 E:562 ||| JJ
vessel  ||| S:562 E:569 ||| NN
trauma ||| S:569 E:575 ||| NN
.  ||| S:575 E:577 ||| .
One  ||| S:577 E:581 ||| CD
of  ||| S:581 E:584 ||| IN
the  ||| S:584 E:588 ||| DT
major  ||| S:588 E:594 ||| JJ
contributors  ||| S:594 E:607 ||| NNS
to  ||| S:607 E:610 ||| TO
vessel  ||| S:610 E:617 ||| VB
trauma  ||| S:617 E:624 ||| NN
is  ||| S:624 E:627 ||| VBZ
the  ||| S:627 E:631 ||| DT
damage  ||| S:631 E:638 ||| NN
caused  ||| S:638 E:645 ||| VBN
by  ||| S:645 E:648 ||| IN
balloon  ||| S:648 E:656 ||| NN
dilation  ||| S:656 E:665 ||| NN
during  ||| S:665 E:672 ||| IN
stent  ||| S:672 E:678 ||| JJ
deployment ||| S:678 E:688 ||| NN
.  ||| S:688 E:690 ||| .
In  ||| S:690 E:693 ||| IN
the  ||| S:693 E:697 ||| DT
present  ||| S:697 E:705 ||| JJ
work ||| S:705 E:709 ||| NN
,  ||| S:709 E:711 ||| ,
a  ||| S:711 E:713 ||| DT
Kriging  ||| S:713 E:721 ||| NNP
based  ||| S:721 E:727 ||| VBN
response  ||| S:727 E:736 ||| NN
surface  ||| S:736 E:744 ||| NN
modelling  ||| S:744 E:754 ||| NN
approach  ||| S:754 E:763 ||| NN
has  ||| S:763 E:767 ||| VBZ
been  ||| S:767 E:772 ||| VBN
implemented  ||| S:772 E:784 ||| VBN
to  ||| S:784 E:787 ||| TO
search  ||| S:787 E:794 ||| VB
for  ||| S:794 E:798 ||| IN
optimum  ||| S:798 E:806 ||| JJ
stent  ||| S:806 E:812 ||| JJ
deployment  ||| S:812 E:823 ||| NN
strategies  ||| S:823 E:834 ||| NNS
in  ||| S:834 E:837 ||| IN
a  ||| S:837 E:839 ||| DT
clinically  ||| S:839 E:850 ||| JJ
challenging ||| S:850 E:861 ||| NN
,  ||| S:861 E:863 ||| ,
patient  ||| S:863 E:871 ||| JJ
specific  ||| S:871 E:880 ||| JJ
diseased  ||| S:880 E:889 ||| JJ
coronary  ||| S:889 E:898 ||| JJ
artery ||| S:898 E:904 ||| NN
.  ||| S:904 E:906 ||| .
In  ||| S:906 E:909 ||| IN
particular ||| S:909 E:919 ||| JJ
,  ||| S:919 E:921 ||| ,
the  ||| S:921 E:925 ||| DT
aims  ||| S:925 E:930 ||| NNS
of  ||| S:930 E:933 ||| IN
this  ||| S:933 E:938 ||| DT
study  ||| S:938 E:944 ||| NN
were ||| S:944 E:948 ||| VBD
:  ||| S:948 E:950 ||| :
( ||| S:950 E:951 ||| -LRB-
i ||| S:951 E:952 ||| FW
)  ||| S:952 E:954 ||| -RRB-
to  ||| S:954 E:957 ||| TO
understand  ||| S:957 E:968 ||| VB
the  ||| S:968 E:972 ||| DT
impact  ||| S:972 E:979 ||| NN
of  ||| S:979 E:982 ||| IN
the  ||| S:982 E:986 ||| DT
balloon  ||| S:986 E:994 ||| NN
pressure  ||| S:994 E:1003 ||| NN
and  ||| S:1003 E:1007 ||| CC
unpressurised  ||| S:1007 E:1021 ||| JJ
diameter  ||| S:1021 E:1030 ||| NN
on  ||| S:1030 E:1033 ||| IN
stent  ||| S:1033 E:1039 ||| JJ
malapposition ||| S:1039 E:1052 ||| NN
,  ||| S:1052 E:1054 ||| ,
drug  ||| S:1054 E:1059 ||| NN
distribution  ||| S:1059 E:1072 ||| NN
and  ||| S:1072 E:1076 ||| CC
wall  ||| S:1076 E:1081 ||| NN
stresses  ||| S:1081 E:1090 ||| VBZ
via  ||| S:1090 E:1094 ||| IN
computer  ||| S:1094 E:1103 ||| NN
simulations  ||| S:1103 E:1115 ||| NNS
and  ||| S:1115 E:1119 ||| CC
( ||| S:1119 E:1120 ||| -LRB-
ii ||| S:1120 E:1122 ||| LS
)  ||| S:1122 E:1124 ||| -RRB-
obtain  ||| S:1124 E:1131 ||| VB
potentially  ||| S:1131 E:1143 ||| RB
optimal  ||| S:1143 E:1151 ||| JJ
dilation  ||| S:1151 E:1160 ||| JJ
protocols  ||| S:1160 E:1170 ||| NNS
to  ||| S:1170 E:1173 ||| TO
simultaneously  ||| S:1173 E:1188 ||| RB
minimise  ||| S:1188 E:1197 ||| JJ
stent  ||| S:1197 E:1203 ||| JJ
malapposition  ||| S:1203 E:1217 ||| NN
and  ||| S:1217 E:1221 ||| CC
tissue  ||| S:1221 E:1228 ||| NN
wall  ||| S:1228 E:1233 ||| NN
stresses  ||| S:1233 E:1242 ||| NNS
and  ||| S:1242 E:1246 ||| CC
maximise  ||| S:1246 E:1255 ||| JJ
drug  ||| S:1255 E:1260 ||| NN
diffusion  ||| S:1260 E:1270 ||| NN
in  ||| S:1270 E:1273 ||| IN
the  ||| S:1273 E:1277 ||| DT
tissue ||| S:1277 E:1283 ||| NN
.  ||| S:1283 E:1285 ||| .
The  ||| S:1285 E:1289 ||| DT
results  ||| S:1289 E:1297 ||| NNS
indicate  ||| S:1297 E:1306 ||| VBP
that  ||| S:1306 E:1311 ||| IN
SM  ||| S:1311 E:1314 ||| NNP
is  ||| S:1314 E:1317 ||| VBZ
inversely  ||| S:1317 E:1327 ||| RB
proportional  ||| S:1327 E:1340 ||| VBN
to  ||| S:1340 E:1343 ||| TO
tissue  ||| S:1343 E:1350 ||| NN
stresses  ||| S:1350 E:1359 ||| NNS
and  ||| S:1359 E:1363 ||| CC
drug  ||| S:1363 E:1368 ||| NN
deliverability ||| S:1368 E:1382 ||| NN
.  ||| S:1382 E:1384 ||| .
After  ||| S:1384 E:1390 ||| IN
analytical  ||| S:1390 E:1401 ||| JJ
multi-objective  ||| S:1401 E:1417 ||| JJ
optimisation ||| S:1417 E:1429 ||| NN
,  ||| S:1429 E:1431 ||| ,
a  ||| S:1431 E:1433 ||| DT
set  ||| S:1433 E:1437 ||| NN
of  ||| S:1437 E:1440 ||| IN
non-dominated  ||| S:1440 E:1454 ||| JJ
dilation  ||| S:1454 E:1463 ||| JJ
scenarios  ||| S:1463 E:1473 ||| NNS
was  ||| S:1473 E:1477 ||| VBD
proposed  ||| S:1477 E:1486 ||| VBN
as  ||| S:1486 E:1489 ||| IN
a  ||| S:1489 E:1491 ||| DT
post-optimisation  ||| S:1491 E:1509 ||| JJ
methodology  ||| S:1509 E:1521 ||| NN
for  ||| S:1521 E:1525 ||| IN
protocol  ||| S:1525 E:1534 ||| JJ
selection ||| S:1534 E:1543 ||| NN
.  ||| S:1543 E:1545 ||| .
Using  ||| S:1545 E:1551 ||| VBG
this  ||| S:1551 E:1556 ||| DT
method ||| S:1556 E:1562 ||| NN
,  ||| S:1562 E:1564 ||| ,
it  ||| S:1564 E:1567 ||| PRP
has  ||| S:1567 E:1571 ||| VBZ
been  ||| S:1571 E:1576 ||| VBN
shown  ||| S:1576 E:1582 ||| VBN
that ||| S:1582 E:1586 ||| IN
,  ||| S:1586 E:1588 ||| ,
for  ||| S:1588 E:1592 ||| IN
a  ||| S:1592 E:1594 ||| DT
given  ||| S:1594 E:1600 ||| VBN
patient  ||| S:1600 E:1608 ||| JJ
specific  ||| S:1608 E:1617 ||| JJ
model ||| S:1617 E:1622 ||| NN
,  ||| S:1622 E:1624 ||| ,
optimal  ||| S:1624 E:1632 ||| JJ
stent  ||| S:1632 E:1638 ||| JJ
expansion  ||| S:1638 E:1648 ||| NN
can  ||| S:1648 E:1652 ||| MD
be  ||| S:1652 E:1655 ||| VB
predicted ||| S:1655 E:1664 ||| VBN
.  ||| S:1664 E:1666 ||| .
Such  ||| S:1666 E:1671 ||| PDT
a  ||| S:1671 E:1673 ||| DT
framework  ||| S:1673 E:1683 ||| NN
could  ||| S:1683 E:1689 ||| MD
potentially  ||| S:1689 E:1701 ||| RB
be  ||| S:1701 E:1704 ||| VB
used  ||| S:1704 E:1709 ||| VBN
by  ||| S:1709 E:1712 ||| IN
interventional  ||| S:1712 E:1727 ||| JJ
cardiologists  ||| S:1727 E:1741 ||| NN
to  ||| S:1741 E:1744 ||| TO
minimise  ||| S:1744 E:1753 ||| VB
stent  ||| S:1753 E:1759 ||| JJ
malapposition  ||| S:1759 E:1773 ||| NN
and  ||| S:1773 E:1777 ||| CC
tissue  ||| S:1777 E:1784 ||| NN
stresses  ||| S:1784 E:1793 ||| VBZ
whilst  ||| S:1793 E:1800 ||| JJ
maximising  ||| S:1800 E:1811 ||| JJ
drug  ||| S:1811 E:1816 ||| NN
deliverability  ||| S:1816 E:1831 ||| NN
in  ||| S:1831 E:1834 ||| IN
any  ||| S:1834 E:1838 ||| DT
patient-specific  ||| S:1838 E:1855 ||| JJ
case ||| S:1855 E:1859 ||| NN
.  ||| S:1859 E:1861 ||| .
